Mironid is a company developing first-in-class small molecule therapeutics for autosomal dominant polycystic kidney disease, one of the most common hereditary kidney disorders.
Its lead programme targets long-form PDE4 enzymes to modulate cyclic AMP signalling, the central driver of cyst growth across all disease stages.
Spun out of the University of Strathclyde and Heriot-Watt University in 2014, the company has raised £35 million to date and is progressing its lead molecule through IND-enabling studies.
Latest News
Mironid Doses First Cohorts in Phase 1 Trial of LoAc Candidate for ADPKD
Mironid has dosed the initial cohorts in its Phase 1 trial of its first-in-class LoAc small molecule for Autosomal Dominant Polycystic Kidney Disease, marking its transition to a clinical-stage company. The dose-escalation study in healthy volunteers is evaluating safety, tolerability and pharmacokinetics, with its single ascending dose part designed to enrol up to 48 participants across six cohorts.
Mironid Raises €39.9M Series B for Rare Kidney Disease Treatment
Mironid has closed a €39.9 million ($46 million) Series B round to advance its lead candidate for Autosomal Dominant Polycystic Kidney Disease through clinical development. The round was led by the Scottish National Investment Bank, joined by existing backers including Roche Venture Fund, Epidarex Capital, and Sofinnova Partners, bringing total funding since inception to €40.8 million.